

ORIGINAL ARTICLE

IP₃ accumulation and/or inositol depletion: two downstream lithium's effects that may mediate its behavioral and cellular changes

Y Sade^{1,2,3,4}, L Toker⁵, NZ Kara^{1,2,3,6}, H Einat⁶, S Rapoport⁷, D Moechars⁸, GT Berry⁹, Y Bersudsky^{2,3,4} and G Agam^{1,2,3,4}

Lithium is the prototype mood stabilizer but its mechanism is still unresolved. Two hypotheses dominate—the consequences of lithium's inhibition of inositol monophosphatase at therapeutically relevant concentrations (the 'inositol depletion' hypothesis), and of glycogen-synthase kinase-3. To further elaborate the inositol depletion hypothesis that did not decisively determine whether inositol depletion *per se*, or phosphoinositols accumulation induces the beneficial effects, we utilized knockout mice of either of two inositol metabolism-related genes—*IMPA1* or *SMIT1*, both mimic several lithium's behavioral and biochemical effects. We assessed *in vivo*, under non-agonist-stimulated conditions, ³H-inositol incorporation into brain phosphoinositols and phosphoinositides in wild-type, lithium-treated, *IMPA1* and *SMIT1* knockout mice. Lithium treatment increased frontal cortex and hippocampal phosphoinositols labeling by several fold, but decreased phosphoinositides labeling in the frontal cortex of the wild-type mice of the *IMPA1* colony strain by ~50%. Inositol metabolites were differently affected by *IMPA1* and *SMIT1* knockout. Inositoltrisphosphate administered intracerebroventricularly affected bipolar-related behaviors and autophagy markers in a lithium-like manner. Namely, IP₃ but not IP₁ reduced the immobility time of wild-type mice in the forced swim test model of antidepressant action by 30%, an effect that was reversed by an antagonist of all three IP₃ receptors; amphetamine-induced hyperlocomotion of wild-type mice (distance traveled) was 35% reduced by IP₃ administration; IP₃ administration increased hippocampal messenger RNA levels of Beclin-1 (required for autophagy execution) and hippocampal and frontal cortex protein levels ratio of Beclin-1/p62 by about threefold (p62 is degraded by autophagy). To conclude, lithium affects the phosphatidylinositol signaling system in two ways: depleting inositol, consequently decreasing phosphoinositides; elevating inositol monophosphate levels followed by phosphoinositols accumulation. Each or both may mediate lithium-induced behavior.

Translational Psychiatry (2016) 6, e968; doi:10.1038/tp.2016.217; published online 6 December 2016

INTRODUCTION

Bipolar disorder (BPD) is a mental illness characterized by severe high and low moods. For ~70 years, lithium salts (lithium, Li) have been the mainstay mood-stabilizing drug. Yet, the drug's therapeutic mechanism at the molecular level has not yet been resolved.¹ The discovery of the inhibitory effect of therapeutically relevant Li concentration on inositol monophosphatase-1 (IMPase-1)² led to the inositol depletion hypothesis of Li's beneficial effect in BPD.³ Needless to say that additional hypotheses have been raised, for example, inhibition of glycogen-synthase-kinase-3 and inhibition of adenylyl-cyclase,⁴ neither of which has been either confirmed or rejected beyond doubt. The inositol depletion hypothesis, dealt with in the present study, suggests that the uncompetitive inhibition of IMPase-1 causes modulation of brain levels of inositol and its metabolites resulting in reduced signaling capacity, but it has not decisively determined whether inositol depletion *per se* or phosphoinositol accumulation induces the

drug's beneficial effects. Some studies^{5,6} suggested that rather than inositol depletion increased brain phosphoinositols levels following IMPase-1 inhibition mediate Li's therapeutic action. Up until now observations related to the inositol depletion hypothesis are inconsistent and do not prove or refute the hypothesis. Observations that support the inositol depletion hypothesis include the following: (i) therapeutically relevant Li concentrations could directly inhibit purified IMPase from different sources;² (ii) Li reduced brain inositol levels⁷ and elevated inositol monophosphate (IP₁), the substrate of IMPase, in rat cortex;^{7,8} (iii) Li administration reduced sodium-*myo*-inositol transporter 1 (*SMIT1*) messenger RNA (mRNA) levels and lowered inositol uptake in astrocyte cultures,^{9–12} (iv) studies demonstrated Li inhibition of IMPase and elevated IP₁ levels in rat cortex slices;¹³ (v) some cellular and behavioral effects of Li such as increasing growth cone area,¹⁴ enhancing autophagy,¹⁵ suppression of rearing in rats^{16,17} and hypersensitivity to pilocarpine-induced seizures were

¹Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva, Israel; ²Psychiatry Research Unit, Ben-Gurion University of the Negev, Beer-Sheva, Israel; ³Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; ⁴Mental Health Center, Beer-Sheva, Israel; ⁵Department of Psychiatry and Centre for High-Throughput Biology, University of British Columbia Vancouver, BC, Canada; ⁶School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Tel Aviv, Israel; ⁷Brain Physiology and Metabolism Section, Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; ⁸Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium and ⁹Metabolism Program Division of Genetics, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA. Correspondence: Professor, G Agam, Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev or Psychiatry Research Unit, Ben-Gurion University of the Negev or Faculty of Health Sciences, Ben-Gurion University of the Negev or Mental Health Center, Beer-Sheva 84170, Israel. E-mail: galila@bgu.ac.il

Received 16 May 2016; revised 17 August 2016; accepted 12 September 2016

reversed by inositol;^{16,17} (vi) reduced brain inositol levels and increased IP₁ levels have been reported in BPD patients treated chronically or acutely with Li compared with healthy controls;^{18,19} (vii) Li treatment of BPD patients reduced phosphatidylinositol bisphosphate (PIP₂) levels in their platelet membranes;²⁰ and (viii) Abbott *et al.*²¹ found that SMIT1 and potassium channel subunits formed complexes and reciprocally regulated each other in the choroid plexus epithelium affecting neuronal excitability. Nevertheless, there are findings that cast some doubt on the inositol depletion hypothesis including: (i) SMIT1 homozygote knockout (KO) mice in which brain inositol levels are ~60% reduced²² do not exhibit the expected reduction in brain phosphatidylinositol (PI) level;²³ (ii) the effect of Li on brain IP₃ levels is species-specific, resulting in either reduced or increased levels;²⁴ (iii) some studies failed to demonstrate reduced brain inositol levels following chronic or acute Li treatment of patients;^{25,26} (iv) KO mice lacking IMPA1 (encoding for IMPase-1, the brain abundant IMPase that is inhibited by therapeutically relevant Li concentrations²⁷) do not exhibit lower frontal cortex or hippocampal inositol levels though brain IMPase activity is decreased by >50%;^{28,29} (v) some behavioral data are also incongruent, for example, acute inositol administration did not block the effect of Li in the mouse forced swim test (FST)³⁰ and *myo*-inositol-1-phosphate (MIP) synthase inhibition did not replicate or augment the effects of Li on pilocarpine-induced seizures;³¹ (vi) neither genome-wide association studies nor genomics investigations report findings related either to the PI signaling system or SMIT1 in BPD or Li treatment;^{4,32} and (vii) genetic studies found variability at IMPA2 but not IMPA1 associated with disease susceptibility, with variation in Li treatment response,^{33,34} with the emergence of suicide behavior in BPD³⁵ and with increased transcription of the IMPA2 allele that harbored a specific haplotype in the frontal cortex of BPD patients.³⁶ These inconsistencies may reflect a delicate system homeostasis possibly influenced by experimental conditions, methodologies used and/or animal strains. Whitworth *et al.*³⁷ attempted to address these inconsistencies by studying the effect of Li on inositol turnover rather than inositol levels *per se*. They examined the effects of acute and chronic Li treatment in combined extracts of mouse cortex and hippocampus following stimulation with the muscarinic cholinergic agonist, pilocarpine. They reported that acute Li treatment resulted in the accumulation of phosphoinositols that was further enhanced by pilocarpine. Increased phosphoinositides levels were only observed following combined acute treatment with Li and pilocarpine.³⁷ Contrarily, when chronic Li treatment was studied, only combined Li +pilocarpine treatment increased phosphoinositols accumulation, whereas phosphoinositides accumulation was observed following Li treatment only.³⁷ Others reported that acute Li treatment in rodents resulted in elevated brain phosphoinositols but decreased phosphoinositides levels.³⁸ We therefore sought a new approach to assess the inositol depletion hypothesis and to address the above issues.

IMPA1 KO and *Slc5a3* (SMIT1, encoding sodium-*myo*-inositol-transporter) KO mice display behavioral characteristics similar to Li-treated wild-type (WT) mice,²⁹ supporting the inositol depletion hypothesis, but somewhat different patterns of brain inositol metabolism.^{28,29,39} These mutant mice offer a unique way to further examine the inositol depletion hypothesis. We assessed brain cytosolic ³H-phosphoinositols accumulation and incorporation into membrane-bound ³H-phosphoinositides following the administration of ³H-inositol intracerebroventricularly (ICV) to WT controls, Li-treated WT mice, and IMPA1 and SMIT1 KO mice to address the central question of what are the *in vivo* downstream consequences of Li's inhibition of IMPase-1 (ref. 27) and inositol depletion reduced re-synthesis of phosphoinositides,³ accumulation of phosphoinositols^{6,40-42} and/or attenuated inositol turnover?^{37,38} Similar *in vivo* studies in Li-treated mice only were previously reported.^{24,37,38,41,43}

Inositol-monophosphate (IP₁) accumulation as a result of Li inhibition of IMPase-1 is well established,^{3,37,38,40,41,44} but whether, concomitantly, levels of other phosphoinositols and the second messenger IP₃, in particular, are affected is uncertain. As the first part of the current study demonstrated increased phosphoinositols accumulation in Li-treated and *IMPA1* KO mice, we further studied whether ICV administration of IP₃ or IP₁ in liposomes induces Li-like behavior.

IP₃'s effects are mediated by its receptors (IP₃Rs—IP₃R1/2/3).⁴⁵ We found that IP₃ but not IP₁ reduced immobility in the FST, an effect that could be reversed by an antagonist of all three IP₃Rs, xestospongine-C (IP₃R_{ant}). IP₃ also attenuated amphetamine-induced hyperactivity.

It has been reported that in cells in culture Li upregulated autophagy in an inositol-dependent manner.¹⁵ Upregulated autophagy had beneficial effects in animal models of affective disorders^{46,47} and could be mimicked *in vitro* by the administration of IP₃Rs antagonists or short interfering RNA targeting IP₃Rs.^{48,49} *In vivo*, knockdown of IP₃Rs using specific antisense oligonucleotides led to an antidepressant-like effect in the FST.⁵⁰ Given our result in the first and second part of the study, we tested the effect of IP₃ on the levels of autophagy markers. IP₃ induced changes in the autophagy markers Beclin-1 and p62, indicative of enhanced autophagy.

MATERIALS AND METHODS

Blinding

All experiments were carried out by the experimenter (YS aided at times by LT and NK) in a blind manner, namely, blinded to the group an animal/sample belonged to until all results of a given experiment were obtained.

Animals

SMIT1 and IMPA1 KO mice were generated as described²⁹ and as recently detailed.³² In short, IMPA1- and SMIT1-KO mice were created on a different C57bl/6 substrain background. Therefore, each of the KOs is maintained in a separate colony. All experiments were approved by the Ben-Gurion University Animal Experimentation Ethics Committee (protocols # IL-02-01-2010, IL-32-05-2012, IL-07-03-2013 and IL-13-04-2013) and were carried out according to the NIH Guide for Care and Use of Laboratory Animals. For experiments not performed in the KO strains, ICR mice (Harlan, Israel or USA) were used. Eight-week-old male mice were used throughout the study. When the KO colonies were used littermate mice were included in all groups of a given experiment.

Lithium treatment

Acute and chronic Li administration. Acute administration: ICR mice (Harlan, USA) or WT mice of the IMPA1 colony were treated with intraperitoneal (i.p.) injection of LiCl at a dose of 3.0 or 10.0 meq/kg, 10 ml/kg, or a similar volume of saline (control) 24 hours prior to euthanasia and brain extraction for the assessment of phosphoinositols accumulation. Twenty hours prior to death mice were injected ICV with 4 μ Ci [³H]-inositol in 1 μ l of inositol (20 mg/ml in artificial cerebrospinal fluid (aCSF)) at a rate of 0.5 μ l/20 sec. Chronic administration: ICR mice, WT untreated mice, IMPA1 KOs and SMIT1 KOs received powdered rodent chaw (Harlan, Israel). Lithium-treated groups received the same powdered chaw mixed with 0.2% lithium chloride (LiCl) for 5 days followed by 0.4% LiCl for 10 additional days.⁵¹ All groups received tap water *ad libitum* and an additional bottle containing 0.9% NaCl to prevent electrolyte imbalance.

[³H]-inositol ICV injection

Mice were anesthetized with 20% isoflurane (diluted in propylene glycol). An incision was made above the bregma and a 25 G needle was used to create a hole in the scalp above the lateral ventricle, 0.2–0.3 mm posterior to bregma and 1 mm lateral to the midline. A Hamilton syringe with a 27 G needle was used to administer 4 μ Ci [³H]-inositol in 1 μ l of inositol (20 mg ml⁻¹ in aCSF at a rate of 0.5 μ l per 20 s.

Brain phosphoinositols accumulation

Brain phosphoinositols accumulation was assayed according to Whitworth and Kendall⁵² with minor modifications. In brief, mice were given an ICV injection of 4 μ Ci [³H]-inositol 24 h before tissue extraction. Mice were killed by cervical dislocation followed by immediate decapitation and their brains quickly dissected on ice to separate the frontal cortex. Samples were then sonicated in 1 ml ice-cold perchloric acid (10% w/v) for 20–30 s to extract the [³H]-inositol phosphates. Sonicated samples were neutralized with KOH (1.5 M) and left on ice for at least 20 min before centrifugation at 2000 g for 20 min. Then, the supernatant was added to 3 ml Tris buffer (50 mM, pH 7.4), mixed and taken for the analysis of total [³H]-inositol phosphates accumulation by anion-exchange chromatography on Dowex chloride columns. The columns were washed with 15 ml H₂O before elution of the [³H]-inositol phosphates with 5 ml HCl (1 M). Samples were placed in scintillation vials.

Incorporation of ³H-inositol into brain phosphoinositides

The membranous pellet remaining from the initial extraction (above), after discarding the excess supernatant, was mixed with 0.94 ml chloroform: methanol:6 N HCl (100:200:1) followed by further aliquots of chloroform (0.32 ml) and water (0.32 ml) to extract the [³H]-inositol phospholipids. Samples of the chloroform phase containing the phospholipids were transferred into scintillation vials and left to evaporate overnight.

Obtaining final results of phosphoinositols accumulation and inositol incorporation into brain phosphoinositides

Radioactivity in [³H]-inositol phosphates and phospholipids was assessed by liquid scintillation counting. Results were calculated per mg protein in the fraction. Protein concentration was assayed by the Bradford method.⁵³

Values obtained following acute and chronic Li treatment were corrected for the well-established reduction in brain inositol levels, ~30% and ~15%, respectively. Similarly, in SMIT1 KO mice, a correction for 60% reduction in inositol levels³⁹ was carried out. Values were not corrected for IMPA1 KO mice, as no difference has previously been found in their frontal cortex and hippocampal inositol levels.²⁸

Behavioral tests

The FST and the amphetamine-induced hyperlocomotion test were performed on different cohorts of mice as described elsewhere.³⁹

Administration of IP₃/IP₁/IP₃R_{ant}

Each of IP₃, IP₁ and IP₃R_{ant} were administered ICV trapped in liposomes. Liposomes were used to enhance penetration into cells and to protect from rapid dephosphorylation of the inositol phosphates before their transport into the cells. Dose–response experiments of IP₃ indicated the appropriate dose to be administered. The results of dose–response analyses in the FST appear in the Supplementary Information.

mRNA and protein levels of autophagy markers

Frontal cortex and hippocampal samples for mRNA and protein extraction were dissected on ice as described before;⁴⁷ mRNA was extracted from mice killed 45 min after IP₃ or aCSF administration and protein was extracted 45 min or 24 h following IP₃ or aCSF administration. A pool of all RNA samples was used for normalization. Table 1 summarizes the primer sequences for the genes examined and the respective efficiencies of their reactions.

Table 1. Primer sequences and reactions' efficiencies

Gene	Sequences	Efficiency
<i>Beclin-1</i>	Fw: GAACTCTGGAGGTCTCGCTC Rev: TAGACCCCTCCATGCCTCAG	113.75%
<i>MAPK6</i>	Fw: TATCGATGAGGTGCAGCTT Rev: GTTCTCGTGGTGATCTGGGT	121.35%

Abbreviations: Fw, forward; Rev, reverse.

Protein concentration was determined spectrophotometrically (Nanodrop, Thermo Scientific, Waltham, MA, USA). Western blotting was performed according to our standard protocol for the same proteins.⁴⁷

Autophagy studies frequently use the conversion of microtubule-associated protein1 light chain 3 (LC3)-I to LC3-II as a marker of changes in the process. However, in mouse brain homogenates, only LC3-I is discernible.^{54,55} We therefore have previously used the ratio between protein levels of two other autophagy markers, Beclin-1 and p62, as readout of autophagy intensity.⁴⁷ The primary antibodies Beclin-1 (#3738, 1:1000, Cell Signaling Technology, Danvers, MA, USA) and p62 (ab56416, 1:1500, Abcam, Cambridge, UK), were diluted in 1 % non-fat dry milk, 1 % bovine serum albumin and 0.01 % sodium azide in Tris-buffered saline Tween 20. Goat anti-rabbit antibodies (sc-2004, 1:10 000, Santa Cruz, Dallas, TX, USA) were diluted in Tris-buffered saline Tween 20. Beclin-1 (encoded by the BECN1) is required for the initiation of the autophagosome formation⁵⁶ and thus is elevated when autophagy is enhanced. p62 (also known as SQSTM1, a ubiquitin-binding scaffold protein⁵⁷) is degraded during the autophagy process and hence its levels are decreased when autophagy is induced.⁵⁷ Thus, an increased Beclin-1/p62 ratio derived from a given sample is suggestive of augmented autophagy.

Statistical analysis

Statistical analyses of the neurochemical results were carried out using one-way analysis of variance (ANOVA) followed by *post hoc* Fisher's least significant difference (LSD) tests. Statistical analyses of the behavioral experiments were performed using either one-way or two-way ANOVA followed by *post hoc* Fisher's LSD tests as indicated in the Results section. The variance in each type of experiment was found to be similar between the groups that were statistically compared. As given in the figures, all groups in all experiments included 5–38 mice per group. It is our long-lasting experience and common knowledge from the literature that to ensure adequate power to detect a biologically meaningful effect size for neurochemical and behavioral experiments at least five animals per group are required. No animals/samples were excluded from the analyses. All analyses were performed using the STATISTICA XI software (Dell Statistica, Tulsa, OK, USA). Level of statistical significance was set at $P \leq 0.05$.

RESULTS

³H-phosphoinositols and ³H-phosphoinositides 24 h following ICV ³H-inositol administration

To better understand whether inositol depletion *per se* or phosphoinositols accumulation mediate Li-induced phenotypes, ³H-inositol was administered ICV to WT-untreated mice, WT mice treated with acute or chronic Li, and to IMPA1 and SMIT1 KO mice. Twenty-four hours later, the levels of ³H-phosphoinositols and ³H-phosphoinositides were measured in the frontal cortex and hippocampus. Details regarding precaution measurements to assure the measurement of a specific biological effect appear under Supplementary Information/Results. The comparison between WT-untreated mice, WT Li-treated and KO mice was performed separately in each of the two colonies (IMPA1 and SMIT1).

Phosphoinositols labeling

In the IMPA1 colony, both chronic Li treatment of WT mice and KO of IMPA1 resulted in a significantly increased ³H-phosphoinositols accumulation. Acute Li treatment induced a non-significant increase and, hence, was not studied in the SMIT1 colony (Figures 1a and b). In the SMIT1 colony, chronic Li treatment but not SMIT1 KO increased phosphoinositols labeling both in the frontal cortex and hippocampus. (Figures 1e and f).

Phosphoinositides labeling

A different pattern was observed for ³H-phosphoinositides accumulation. In the IMPA1 colony, neither Li treatment nor IMPA1 KO affected phosphoinositides labeling (Figures 1c and d). In contrast, in the SMIT1 colony, both chronic Li treatment and SMIT1 KO significantly reduced phosphoinositides labeling in the




Figure 1. Effect of Li treatment and of KO of IMPA1 and SMIT1 on ^3H -inositol incorporation into phosphoinositols (**a, b, e, f**) and phosphoinositides (**c, d, g, h**) in the frontal cortex and hippocampus. ^3H -inositol was administered ICV 24 h before death to WT mice, acutely Li-treated WT mice, chronically Li-treated WT mice, all from the IMPA1 colony, and to IMPA1 KO mice (**a–d**) or to WT mice, and chronically Li-treated WT mice, all from the SMIT1 colony, and to SMIT1 KO mice (**e–h**), and ^3H -phosphoinositols accumulation and incorporation of the radiolabeled inositol into ^3H -phosphoinositides assayed as described under Materials and methods. (**a**) *ANOVA: $F(3,111) = 38.285$, $P < 0.01$; Fisher's LSD *post hoc* analysis: acute Li vs WT, $P = 0.1$; **chronic Li vs WT, $P < 0.01$; ***IMPA1 KO vs WT, $P = 0.002$. (**b**) *ANOVA: $F(3,109) = 13.056$, $P < 0.01$; Fisher's LSD *post hoc* analysis: acute Li vs WT, $P = 0.1$; **chronic Li vs WT, $P < 0.01$; ***IMPA1 KO vs WT, $P < 0.01$. (**c**) ANOVA: $F(3,73) = 0.38312$, $P = 0.765$. (**d**) ANOVA: $F(3,67) = 0.647$, $P = 0.58$. (**e**) *ANOVA: $F(2,41) = 5.8485$, $P < 0.01$; Fisher's LSD *post hoc* analysis: **chronic Li vs WT, $P < 0.01$; SMIT1 KO vs WT, $P = 0.98$. (**f**) *ANOVA: $F(2,39) = 5.0149$, $P = 0.01$; Fisher's LSD *post hoc* analysis: **chronic Li vs WT, $P = 0.02$; SMIT1 KO vs WT, $P = 0.58$. (**g**) *ANOVA: $F(2,37) = 4.932$, $P = 0.01$; Fisher's LSD *post hoc* analysis: **chronic Li vs WT, $P < 0.01$; **SMIT1 KO vs WT, $P = 0.01$. (**h**) ANOVA: $F(2,40) = 0.38$, $P = 0.68$. ANOVA, analysis of variance; ICV, intracerebroventricularly; KO, knockout; Li, lithium; SMIT1, sodium-*myo*-inositol transporter 1; WT, wild type.

frontal cortex (Figure 1g). As the IMPA1 and SMIT1 colonies were created on different genetic backgrounds^{22,28} and the effect of lithium on ^3H -phosphoinositides accumulation was observed only in mice of the SMIT1 colony, it is possible that this effect is genetic background-dependent. No change was observed in the hippocampus (Figure 1h).

The effect of IP₃ on behavior in the FST and amphetamine-induced hyperlocomotion test

We wished to find out whether among the phosphoinositols that accumulate following Li treatment IP₃, a second messengers in the PI signaling system,³ or its metabolite IP₁, which accumulates due to Li's inhibition of IMPase-1,^{7,8} mediate Li-induced behavioral




Figure 2. IP₃ (a) but not IP₁ (b) administered ICV to mice reduced immobility time in the FST and IP₃ attenuated amphetamine-induced hyperlocomotion (c, d). (a, b) Immobility time in the FST 45 min following ICV administration of 150 μg IP₃ (a) or 200 μg of IP₁ (b) (or vehicle (aCSF)), each in liposomes. (a) **t*-test: *t*(26) = 5.65, *P* < 0.03. (b) *t*-test: *t*(19) = 1.59, *P* = 0.22. (c, d) Amphetamine-induced hyperlocomotion. Thirty minutes following ICV administration of 150 μg IP₃ in liposomes, mice were injected (i.p.) 1.5 mg kg⁻¹ amphetamine (amphet) or saline, placed in an open-field box and their activity monitored for 30 min. (c) Two-way ANOVA: IP₃ treatment: *F*(1,52) = 55, *P* = 0.01; amphetamine treatment: *F*(1,52) = 8.67, *P* < 0.01; ***amphetamine × IP₃ interaction: *F*(1,51) = 4.1, *P* < 0.05. (d) Two-way ANOVA with repeated measures: IP₃ treatment: *F*(6,46) = 2.4, *P* = 0.03; amphetamine treatment: *F*(6,46) = 13.7, *P* < 0.01. Two-way ANOVA for each time interval: *amphetamine/IP₃ vs amphetamine/aCSF, *P* < at least 0.016. aCSF, artificial cerebrospinal fluid; ANOVA, analysis of variance; FST, forced swim test; IP, inositol phosphate; i.p., intraperitoneal; ICV, intracerebroventricularly; WT, wild type.

changes in two behavioral paradigms: the FST and the amphetamine-induced hyperlocomotion test. Screening experiments of the possible effect of IP₃ and IP₁ on motor capabilities are described under Supplementary Information/Results. Similarly to chronic Li treatment,^{39,51,58} ICV administration of IP₃ (trapped in liposomes) resulted, 45 min later, in decreased immobility time in the FST (Figure 2a), an antidepressant-like effect,⁵⁹ and in an attenuated response to amphetamine, an antimanic-like effect⁶⁰ (Figures 2c and d). To further assess whether IP₃ directly propagates the signal following Li treatment and/or whether the behavioral effects are mediated by its breakdown product, IP₁, we studied the effect of IP₁ in a similar manner. An amount of 200 μg of IP₁ (higher than the effective dose of IP₃) did not affect the immobility time in the FST as compared with the mice receiving aCSF (Figure 2b). Higher amounts of IP₁ could not be tested due to toxicity. The possibility that IP₁ failed to affect the FST due to its effect on motor activity/coordination was ruled out (Supplementary Information/Results). As IP₁ failed to mimic Li in the FST, we did not study its effect in the amphetamine-induced hyperlocomotion paradigm.

Given the antidepressant-like and antimanic-like behavioral effects of IP₃, mimicking well-established effects of Li, a straightforward assumption was that IP₃ exerts its behavioral effects through its receptors (IP₃R). Thus, we examined whether the administration of xestospongine-C, an antagonist of all three IP₃ receptors (IP₃R_{ant}), reverses these effects. Mice were administered ICV with aCSF, or IP₃, or IP₃R_{ant} or IP₃+IP₃R_{ant}, each trapped in liposomes, 45 min before their exposure to the FST. Administration of IP₃R_{ant} reversed the antidepressant-like effect of IP₃ (Figure 3a). We further hypothesized that Li's behavioral effect in the FST is also reversed by the IP₃R_{ant}. In contrast with our simplistic hypothesis, Li and xestospongine-C exerted a synergistic effect on the immobility time (Figure 3b).

The effect of IP₃ on autophagy markers

IP₃R are involved in the regulation of autophagy,⁴⁹ a cellular process previously shown to be enhanced by Li in an inositol-dependent manner.¹⁵ As the enhancement of autophagy was shown to induce an antidepressant-like effect,^{46,47} we tested whether IP₃ administration also mimics Li treatment at the level of the autophagy process. Autophagy studies frequently use the conversion of microtubule-associated protein1 LC3-I to LC3-II as a marker of changes in the process. However, in mouse brain homogenates, only LC3-I is discernible.^{53,54} We therefore have previously used the ratio between protein levels of two other autophagy markers, Beclin-1 and p62, as a readout of autophagy intensity.⁴⁷ Beclin-1 (encoded by the *BECN1*) is required for the initiation of the autophagosome formation,⁵⁵ and thus is elevated when autophagy is enhanced. p62 (also known as SQSTM1, a ubiquitin-binding scaffold protein⁵⁶), is degraded during the autophagy process and hence its levels are decreased when autophagy is induced.⁵⁶ Thus, an increased Beclin-1/p62 ratio derived from a given sample is suggestive of augmented autophagy.

Forty-five minutes following IP₃ administration, *BECN1* expression was significantly upregulated in the hippocampus but not in the frontal cortex (Figures 4a and b). As protein but not transcript levels of p62 are affected by autophagy, p62 transcript levels were not assessed. Forty-five minutes following IP₃ administration, Beclin-1/p62 ratio was not affected either in the frontal cortex or in the hippocampus (data not shown). However, 24 h following IP₃ treatment, the ratio was elevated both in the hippocampus and in the frontal cortex (Figures 4c and d), in a similar manner to chronically Li-treated and of *IMPA1* KO mice: WT, *n* = 5, 0.56 ± 0.12 (s.e.m.); Li, *n* = 4, 1.67 ± 0.42; *IMPA1* KO, *n* = 7, 1.08 ± 0.15; ANOVA, *F*(2,13) = 5.3, *P* < 0.025; Fisher's LSD *post hoc* analysis, WT vs Li, *P* < 0.03; WT vs *IMPA1* KO, *P* < 0.03).




Figure 3. IP₃R_{ant} administered ICV reversed IP₃'s effect (a) and enhanced Li's effect in the FST (b). (a, b) Immobility time in the FST 45 min following ICV administration of 10 pmol of IP₃R_{ant} in liposomes. (a) Two-way ANOVA: *IP₃ treatment: $F(1,62) = 7.98, P < 0.01$; IP₃R_{ant} treatment: $F(1,62) = 1.78, P = 0.18$; *IP₃ treatment \times IP₃R_{ant} treatment interaction: $F(1,62) = 4.11, P = 0.046$; Fisher's LSD *post hoc* analysis: *IP₃ vs aCSF, $P < 0.01$; *IP₃+IP₃R_{ant} vs IP₃, $P = 0.02$. (b) Two-way ANOVA: *Li treatment: $F(1,59) = 27.03, P < 0.01$; *IP₃R_{ant} treatment: $F(1,59) = 4.7, P = 0.03$; Li treatment \times IP₃R_{ant} treatment interaction: $F(1,59) = 0.83, P = 0.3$; Fisher's LSD *post hoc* analysis: *Li+aCSF vs regular food+aCSF, $P < 0.01$; *Li+IP₃R_{ant} vs Li+aCSF, $P = 0.04$. aCSF, artificial cerebrospinal fluid; ANOVA, analysis of variance; FST, forced swim test; ICV, intracerebroventricularly; IP, inositol phosphate; IP₃R_{ant}, IP₃ receptor antagonist.




Figure 4. ICV administration of IP₃ affected autophagy markers suggestive of an enhanced process. 45 min following ICV administration of IP₃ BECN1 mRNA levels were elevated in the hippocampus (a) but not in frontal cortex (b). Twenty-four hours following ICV administration of IP₃ Beclin-1/p62 protein level ratio was elevated in the hippocampus (c) and in the frontal cortex (d). (a) **t*-test, $t(30) = 24.5, P < 0.01$. (b) *t*-test, $t(18) = 0.89, P = 0.35$. (c) **t*-test, $t(10) = 5.95, P = 0.03$. (d) *One-tailed *t*-test, $t(9) = 3.21, P = 0.05$. aCSF, artificial cerebrospinal fluid; ICV, intracerebroventricularly; IP, inositol phosphate.

DISCUSSION

Li perturbs brain inositol metabolism at several sites.^{2,9,61} The brain may be particularly Li sensitive due to low inositol penetrability of the blood-brain barrier.⁶² Therefore, the brain relies mainly on the recycling and *de novo* synthesis of inositol.³ The response of the PI cycle to Li treatment was extensively investigated using a variety of agonists. However, the reports regarding phosphoinositides and phosphoinositols levels, in general, and IP₃, in particular, are inconsistent. Namely, *ex vivo* studies in brain slices from Li-treated animals following incubation with [³H]-inositol with or without stimulation by receptor agonists and with or without inositol supplementation in the medium reported an increase, a decrease or a lack of effect on [³H]-phosphoinositols production.^{6,63,64} Elevated IP₃ levels have been shown in the cerebral cortex of guinea pigs, rabbits, monkeys, rats

and mice.²⁴ In COS-7 and SK-N-SH cell lines, Sarkar *et al.*¹⁵ reported the reduction of IP₃ levels following Li treatment, whereas in the SH-SY5Y cell line, Los *et al.*⁶⁵ found elevated levels in a dose-dependent manner. These inconsistencies might stem from the following reasons: (i) species and cell type differences, for example, the rodent brain exhibits 50% less inositol compared with primate brain;^{24,66} (ii) while preparing cerebral slices there is 80% loss of inositol and supplementation of 10 mM is required to restore inositol levels.²⁴ This might have shifted the equilibrium among the various phosphoinositols. Thus, results obtained from such experiments might not represent the *in vivo* response.

Beyond the different experimental conditions, it could be that the inconsistencies stem from a more complex mechanism of action of Li than reducing the levels of inositol and phosphoinositides, *per se*. We therefore considered that studying basal state PI

hydrolysis (without agonist stimulation) might better reflect the response to Li. In accordance with the previous reports,^{37,38} we found that chronic Li treatment resulted in a significant increase in ³H-phosphoinositols accumulation both in the frontal cortex and hippocampus, and acute treatment showed a similar trend. In our previous studies, both IMPA1 and SMIT1 KO mice were shown to exhibit Li-like behavior, but only SMIT1 KOs had reduced brain inositol levels.^{28,29,39} This provided the opportunity to decipher whether IP₃ accumulation and/or inositol depletion are the molecular downstream effects of Li mediating its induced behavior. Interestingly, only IMPA1 KO mice mimicked phosphoinositols accumulation seen following Li treatment. These results suggest that both inositol depletion (according to the results in SMIT1 KOs) and phosphoinositols accumulation (according to the results in IMPA1 KOs) may mediate Li-induced behavioral effects. It is notable that in the frontal cortex of SMIT1 KO mice and chronically Li-treated WT mice from the SMIT1 colony phosphoinositides labeling was significantly decreased. This raises the possibility that the attenuation of inositol turnover also mediates Li-induced behavioral effects.

Taken together, the results support the notion that perturbation of several sites along the PI cycle might mediate behavioral consequences of Li treatment. This concept is different from the original inositol depletion hypothesis that assumed, based on the cyclic nature of the PI signaling system, that inositol metabolites of the cycle are mutually regulated and that by targeting a given site of the cycle all its components are influenced. The current findings suggest that the components previously believed to be metabolically interconnected (phosphoinositols, phosphoinositides and free inositol) have separate modes of action by which they affect behavior, and that perturbing a given component would not necessarily affect the others. This possibility is further supported by clinical studies that reported beneficial therapeutic effects of oral inositol supplementation in illnesses responsive to serotonin-selective re-uptake inhibitors, including depression, panic and obsessive-compulsive disorder,⁶⁷ and as an add-on to the ongoing treatment in BPD.⁶⁸ Either inositol supplementation or inhibition of inositol monophosphatase leading to inositol depletion can, concomitantly, result in IP₃ accumulation.

The above conclusion should be taken cautiously as our results are based on a crude method of measuring ³H-inositol incorporation into soluble and insoluble fractions that were not further separated into specific inositol-containing molecules. In the case of the phosphoinositides, there are different types that carry out different functions.⁶⁹ Similarly, there are several molecular moieties of soluble phosphoinositols, and a number of metabolic pathways that interconvert among themselves (as discussed below).

Accumulation of phosphoinositols following Li treatment and in IMPA1 KO mice raised the question do IP₁ or IP₃ mediate the behavioral effects of Li. IP₃ induced an antidepressant-like and Li-like effect in the FST, and an antimanic-like and Li-like effect in the amphetamine-induced hyperlocomotion paradigm. Non-specific behavioral effects of IP₃ were ruled out as detailed under Supplementary Information/Results. It is known that IP₁ accumulation following Li treatment exceeds that of IP₃.⁷⁰ Nevertheless, IP₁ did not exhibit an antidepressant-like effect in the FST at a dose similar to that of IP₃. A threefold higher IP₁ dose was toxic. It is thus conceivable that IP₃ is a downstream mediator of Li- and IMPA1 KO- but not SMIT1 KO-induced behavioral effects.

As IP₃ is known to mediate its effect via binding to IP₃Rs, we hypothesized that IP₃-induced behavioral effects are mediated by its receptors that are found on the endoplasmic reticulum. To test this possibility we used the IP₃R_{ant}, xestospongine-C, which antagonizes all three IP₃Rs.⁵⁰ Similarly to *in vivo* knockdown of IP₃Rs, high xestospongine-C doses were shown to decrease the immobility time in the FST.⁵⁰ To reduce this confounding effect we chose a xestospongine-C dose that does not influence the behavior of mice in this test. As hypothesized, xestospongine-C reversed IP₃'s action in the FST, suggesting that Li's behavioral effects mimicked by IP₃ are mediated via the IP₃Rs. However, whether all three receptors are involved in these behaviors, one of them or a combination of two, remains to be investigated.

Phosphoinositols with more than three phosphate groups (IP₄–IP₆) as well as inositol pyrophosphates (IP₇ and IP₈) are also known to exhibit second messenger characteristics. The enzyme phosphatidylinositol-3-kinase (PI3K) that produces phosphatidylinositol-3,4,5-trisphosphate (PIP₃) is also the main enzyme responsible for the generation of inositol pyrophosphates.⁷¹ We cannot rule out the possibility that IP₃ is further converted into any of IP₄–IP₈ that mediate the behavioral effects induced by administered IP₃ or by enhanced accumulation following Li treatment. However, this possibility is less likely, as inositol polyphosphates and pyrophosphates are not IP₃R agonists.

Surprisingly, when xestospongine-C and Li were co-administered, rather than the expected reversal of Li's antidepressant-like effect in the FST, a synergistic effect was obtained. The synergism may be interpreted as follows. Chronic Li was shown to downregulate IP₃Rs,⁷² possibly as a result of receptor desensitization and internalization following IP₃ accumulation. The dose of xestospongine-C chosen in the present study (10 pmoles) was, by itself, ineffective in the FST, but higher doses (30 pmoles) were shown to decrease the immobility time in the FST.⁵⁰ Thus, combining the lower xestospongine-C dose with Li induces an effect similar to that of a high xestospongine-C dose, namely, an antidepressant-like effect. IP₃R_{ant}'s effects could not be reversed

Table 2. A comparison among the phenotypes of Li-treated mice, SMIT1 KO mice and IMPA1 KO mice

Measure	Li treatment	IMPA1 KO	SMIT1 KO
Brain inositol levels	Reduced	Unchanged	Reduced
Brain IP ₃ accumulation	Elevated	Elevated	Unchanged
Brain phosphoinositide levels	Decreased	Unchanged	Decreased
Autophagy	Enhanced	Enhanced	?
Pilocarpine-induced seizures	Hypersensitive	Hypersensitive	Hypersensitive
FST	Antidepressant-like behavior	Antidepressant-like behavior	Antidepressant-like behavior
Amphetamine-induced hyperlocomotion	Attenuated	?	attenuated

Abbreviations: FST, forced swim test; KO, knockout; Li, lithium. SMIT1 KO but not IMPA1 KO mice exhibited reduced brain inositol levels observed following Li treatment;²⁹ both Li treatment and IMPA1 KO cause enhanced phosphoinositols accumulation (the present study), enhanced autophagy (the present study, and Sarkar *et al.*¹⁵), as well as hypersensitization to pilocarpine-induced seizures and an antidepressant-like effect in the FST;²⁹ both Li-treated mice and SMIT1 KO mice exhibit decreased phosphoinositides labeling (the present study), and SMIT1 KO mice recapitulate the same Li-like behavior in pilocarpine-induced seizures and in the FST and demonstrate, similarly to Li-treated mice, an antimanic-like effect in the amphetamine-induced hyperlocomotion paradigm (unpublished results and Bersudsky *et al.*³⁹).




Figure 5. Suggested mechanisms of Li-induced behavior and enhanced autophagy: 1—according to the results in the SMIT1 KO mice; 2—according to the results in the IMPA1 KO mice; 3—according to de Bartolomeis *et al.*;⁷² 4—according to the results in IP₃-treated mice; 5—a reasonable assumption; 6—according to Vicencio *et al.*;⁴⁹ and 7—according to Kara *et al.*⁴⁷ IP, inositol phosphate; KO, knockout; Li, lithium; PI, phosphatidylinositol.

by inositol supplementation,⁴⁹ suggesting an inositol-independent pathway, enabling synergism with Li's effect that is supposedly mediated by an inositol-dependent mechanism.

Li has been shown to induce autophagy in an mTOR-independent manner accompanied by reduced IP₃ levels, both reversed by inositol supplementation.¹⁵ Rapamycin and trehalose, autophagy inducers, have recently been shown to induce an antidepressant-like decreased immobility in the FST.^{46,47} Our results indicate that similarly to Li-treated WT mice and IMPA1 KO mice (data submitted for publication), IP₃ administration upregulated hippocampal but not frontal cortex *BECN1* mRNA levels 45 min after the administration and elevated Beclin-1/p62 protein level ratio both in the hippocampus and frontal cortex 24 h following the administration. Simplistically, these results contradict those of Sarkar *et al.*,¹⁵ who showed that decreased, rather than elevated, IP₃ levels promote autophagy. However, it is conceivable that the high dose of IP₃ that we administered resulted in desensitization of the IP₃Rs, which have previously been shown to inhibit autophagy by binding Beclin-1.⁴⁹ Thus, similarly to decreased IP₃ levels, IP₃ administered ICV led to changes in autophagy markers indicative of enhanced autophagy. Multiple reviews (for example, Morris *et al.*,⁷³ Scheuing *et al.*⁷⁴ and Motoi *et al.*⁷⁵) hypothesize the beneficial effects of Li treatment in neurodegenerative disorders based on the reports in animal models and cells in culture of Li-induced enhanced autophagy as a mechanism of the drug's neuroprotective characteristic (for example, Fornai *et al.*,⁷⁶ Fabrizi *et al.*⁷⁷ and Sarkar *et al.*⁷⁸). However, to the best of our knowledge, there are no clinical studies where Li's effect on autophagy was assessed in relation to clinical efficacy.

The fact that the Beclin-1/p62 protein level ratio was elevated 24 h but not 45 min following IP₃ administration suggests that IP₃-induced Li-like changes in the levels of autophagy-related proteins occur in parallel rather than upstream to IP₃-induced Li-like behaviors. However, as demonstrated by Vicencio *et al.*,⁴⁹ in addition to the role of IP₃Rs as ion channels, they also function as scaffold proteins for the interaction between Beclin-1 and Bcl2, an interaction that inhibits Beclin-1-induced autophagy. If IP₃ administration indeed leads to desensitization and internalization of IP₃Rs, reduced availability of IP₃Rs would result in decreased interaction between Beclin-1 and Bcl2, and in enhanced autophagy without affecting Beclin-1 levels. Hence, we cannot unequivocally rule out the possibility that 45 min following IP₃

administration autophagy was increased but not reflected in an increased beclin1/p62 ratio.

Taken together, accumulated results in Li-treated mice and transgenic mice (Table 2 and its detailed description), and in IP₃-treated mice, prompt us to suggest the cascade of events mediating Li's neurochemical, cellular and behavioral effects depicted in Figure 5. Namely, Li-induced behavior may be mediated by reduced inositol levels, or by reduced phosphoinositides levels (according to the results in the SMIT1 KO mice) or by IP₃ accumulation (according to the results in the IMPA1 KO mice and IP₃-treated mice). Partially corroborating Sarkar *et al.*,¹⁵ Li-induced enhanced autophagy may be mediated by IP₃ accumulation, possibly causing IP₃Rs desensitization, and by direct IP₃Rs downregulation.⁷²

To sum-up, the present study utilized genetic tools combined with behavioral models, biochemical assays and cellular processes evaluation in an attempt to revisit the inositol depletion hypothesis of Li's molecular mechanism of action. Both phosphoinositols accumulation and reduced phosphoinositides levels were demonstrated. IP₃ is a highly probable main phosphoinositol but higher phosphorylated inositol moieties may not be ruled out. Whether Li-induced enhanced autophagy mediates the drug's behavioral effects or is a parallel phenomenon requires further investigation.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

The advice of Drs Nava Bashan and Alon Freedman from the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel and of Dr Alon Shamir from the Psychobiology Research Laboratory, Mazra Mental Health Center, Akko and The Ruth and Bruce Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Haifa, Israel is deeply appreciated.

REFERENCES

- Can A, Schulze TG, Gould TD. Molecular actions and clinical pharmacogenetics of lithium therapy. *Pharmacol Biochem Behav* 2014; **123**: 3–16.
- Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. *J Biol Chem* 1980; **255**: 10896–10901.
- Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. *Cell* 1989; **59**: 411–419.
- Alda M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. *Mol Psychiatry* 2015; **20**: 661–670.
- Agranoff BW, Fisher SK. Inositol, lithium, and the brain. *Psychopharmacol Bull* 2001; **35**: 5–18.
- Dixon JF, Hokin LE. Lithium stimulates accumulation of second-messenger inositol 1,4,5-trisphosphate and other inositol phosphates in mouse pancreatic minilobules without inositol supplementation. *Biochem J* 1994; **304**(Pt 1): 251–258.
- Allison JH, Blisner ME. Inhibition of the effect of lithium on brain inositol by atropine and scopolamine. *Biochem Biophys Res Commun* 1976; **68**: 1332–1338.
- Sherman WR, Leavitt AL, Honchar MP, Hallcher LM, Phillips BE. Evidence that lithium alters phosphoinositide metabolism: chronic administration elevates primarily D-myo-inositol-1-phosphate in cerebral cortex of the rat. *J Neurochem* 1981; **36**: 1947–1951.
- van Calker D, Belmaker RH. The high affinity inositol transport system—implications for the pathophysiology and treatment of bipolar disorder. *Bipolar Disord* 2000; **2**: 102–107.
- Lubrich B, van Calker D. Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? *Neuropsychopharmacology* 1999; **21**: 519–529.
- Lubrich B, Spleiss O, Gebicke-Haerter PJ, van Calker D. Differential expression, activity and regulation of the sodium/myo-inositol cotransporter in astrocyte cultures from different regions of the rat brain. *Neuropharmacology* 2000; **39**: 680–690.
- Wolfson M, Bersudsky Y, Zinger E, Simkin M, Belmaker RH, Hertz L. Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic

- acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. *Brain Res* 2000; **855**: 158–161.
- 13 Batty I, Nahorski SR. Differential effects of lithium on muscarinic receptor stimulation of inositol phosphates in rat cerebral cortex slices. *J Neurochem* 1985; **45**: 1514–1521.
- 14 Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. *Nature* 2002; **417**: 292–295.
- 15 Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M et al. Lithium induces autophagy by inhibiting inositol monophosphatase. *J Cell Biol* 2005; **170**: 1101–1111.
- 16 Kofman O, Belmaker RH. Intracerebroventricular myo-inositol antagonizes lithium-induced suppression of rearing behaviour in rats. *Brain Res* 1990; **534**: 345–347.
- 17 Kofman O, Belmaker RH, Grisaru N, Alpert C, Fuchs I, Katz V et al. Myo-inositol attenuates two specific behavioral effects of acute lithium in rats. *Psychopharmacol Bull* 1991; **27**: 185–190.
- 18 Moore CM, Breeze JL, Gruber SA, Babb SM, Frederick BB, Villafuerte RA et al. Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex. *Bipolar Disord* 2000; **2**(3 Pt 2): 207–216.
- 19 Davanzo P, Thomas MA, Yue K, Oshiro T, Belin T, Strober M et al. Decreased anterior cingulate myo-inositol/creatinine spectroscopy resonance with lithium treatment in children with bipolar disorder. *Neuropsychopharmacology* 2001; **24**: 359–369.
- 20 Soares JC, Mallinger AG, Dippold CS, Forster Wells K, Frank E, Kupfer DJ. Effects of lithium on platelet membrane phosphoinositides in bipolar disorder patients: a pilot study. *Psychopharmacology* 2000; **149**: 12–16.
- 21 Abbott GW, Tai KK, Neverisky DL, Hansler A, Hu Z, Roepke TK et al. KCNQ1, KCNE2, and Na⁺-coupled solute transporters form reciprocally regulating complexes that affect neuronal excitability. *Sci Signal* 2014; **7**: ra22.
- 22 Berry GT, Wu S, Buccafusca R, Ren J, Gonzales LW, Ballard PL et al. Loss of murine Na⁺/myo-inositol cotransporter leads to brain myo-inositol depletion and central apnea. *J Biol Chem* 2003; **278**: 18297–18302.
- 23 Buccafusca R, Venditti CP, Kenyon LC, Johanson RA, Van Bockstaele E, Ren J et al. Characterization of the null murine sodium/myo-inositol cotransporter 1 (Smit1 or Slc5a3) phenotype: myo-inositol rescue is independent of expression of its cognate mitochondrial ribosomal protein subunit 6 (Mrps6) gene and of phosphatidylinositol levels in neonatal brain. *Mol Genet Metab* 2008; **95**: 81–95.
- 24 Lee CH, Dixon JF, Reichman M, Moumni C, Los G, Hokin LE. Li⁺ increases accumulation of inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate in cholinergically stimulated brain cortex slices in guinea pig, mouse and rat. The increases require inositol supplementation in mouse and rat but not in guinea pig. *Biochem J* 1992; **282**(Pt 2): 377–385.
- 25 Shapiro J, Belmaker RH, Biegona A, Seker A, Agam G. Scyllo-inositol in post-mortem brain of bipolar, unipolar and schizophrenic patients. *J Neural Transm*. 2000; **107**: 603–607.
- 26 Silverstone PH, Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC. Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients. *Hum Psychopharmacol* 2002; **17**: 321–327.
- 27 Ohnishi T, Ohba H, Seo KC, Im J, Sato Y, Iwayama Y et al. Spatial expression patterns and biochemical properties distinguish a second myo-inositol monophosphatase IMPA2 from IMPA1. *J Biol Chem* 2007; **282**: 637–646.
- 28 Cryns K, Shamir A, Van Acker N, Levi I, Daneels G, Goris I et al. IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity. *Neuropsychopharmacology* 2008; **33**: 674–684.
- 29 Agam G, Bersudsky Y, Berry GT, Moechars D, Lavi-Avnon Y, Belmaker RH. Knockout mice in understanding the mechanism of action of lithium. *Biochem Soc Trans* 2009; **37**(Pt 5): 1121–1125.
- 30 Toker L, Kara N, Hadas I, Einat H, Bersudsky Y, Belmaker RH et al. Acute intracerebroventricular inositol does not reverse the effect of chronic lithium treatment in the forced swim test. *Neuropsychobiology* 2013; **68**: 189–192.
- 31 Einat H, Tian F, Belmaker RH, Frost JW. Myo-inositol-1-phosphate (MIP) synthase inhibition: *in-vivo* study in rats. *J Neural Transm* 2008; **115**: 55–58.
- 32 Toker L, Bersudsky Y, Plaschkes I, Chalifa-Caspi V, Berry GT, Buccafusca R et al. Inositol-related gene knockouts mimic lithium's effect on mitochondrial function. *Neuropsychopharmacology* 2014; **39**: 319–328.
- 33 Sjholt G, Ebstein RP, Lie RT, Berle JO, Mallet J, Deleuze JF et al. Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder. *Mol Psychiatry* 2004; **9**: 621–629.
- 34 Sjholt G, Gulbrandsen AK, Lovlie R, Berle JO, Molven A, Steen VM. A human myo-inositol monophosphatase gene (IMPA2) localized in a putative susceptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients. *Mol Psychiatry* 2000; **5**: 172–180.
- 35 Jimenez E, Arias B, Mitjans M, Goikolea JM, Roda E, Saiz PA et al. Genetic variability at IMPA2, INPP1 and GSK3beta increases the risk of suicidal behavior in bipolar patients. *Eur Neuropsychopharmacol* 2013; **23**: 1452–1462.
- 36 Ohnishi T, Yamada K, Ohba H, Iwayama Y, Toyota T, Hattori E et al. A promoter haplotype of the inositol monophosphatase 2 gene (IMPA2) at 18p11.2 confers a possible risk for bipolar disorder by enhancing transcription. *Neuropsychopharmacology* 2007; **32**: 1727–1737.
- 37 Whitworth P, Heal DJ, Kendall DA. The effects of acute and chronic lithium treatment on pilocarpine-stimulated phosphoinositide hydrolysis in mouse brain *in vivo*. *Br J Pharmacol* 1990; **101**: 39–44.
- 38 Sun GY, Navidi M, Yoa FG, Lin TN, Orth OE, Stubbs EB Jr. et al. Lithium effects on inositol phospholipids and inositol phosphates: evaluation of an *in vivo* model for assessing polyphosphoinositide turnover in brain. *J Neurochem* 1992; **58**: 290–297.
- 39 Bersudsky Y, Shaldubina A, Agam G, Berry GT, Belmaker RH. Homozygote inositol transporter knockout mice show a lithium-like phenotype. *Bipolar Disord* 2008; **10**: 453–459.
- 40 Allison JH. Lithium and brain myo-inositol metabolism. In: Wells WW, Eisenberg F (eds). *Cyclitols and Phosphoinositides*. Academic Press: New York, USA, 1978.
- 41 Allison JH, Blisner ME, Holland WH, Hipps PP, Sherman WR. Increased brain myo-inositol 1-phosphate in lithium-treated rats. *Biochem Biophys Res Commun* 1976; **71**: 664–670.
- 42 Allison JH, Boshans RL, Hallcher LM, Packman PM, Sherman WR. The effects of lithium on myo-inositol levels in layers of frontal cerebral cortex, in cerebellum, and in corpus callosum of the rat. *J Neurochem* 1980; **34**: 456–458.
- 43 Sherman WR, Gish BG, Honchar MP, Munsell LY. Effects of lithium on phosphoinositide metabolism *in vivo*. *Fed Proc* 1986; **45**: 2639–2646.
- 44 Sherman WR, Munsell LY, Gish BG, Honchar MP. Effects of systemically administered lithium on phosphoinositide metabolism in rat brain, kidney, and testis. *J Neurochem* 1985; **44**: 798–807.
- 45 Berridge MJ. Inositol trisphosphate and calcium signalling. *Nature* 1993; **361**: 315–325.
- 46 Cleary C, Linde JA, Hiscock KM, Hadas I, Belmaker RH, Agam G et al. Antidepressant-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders. *Brain Res Bull* 2008; **76**: 469–473.
- 47 Kara NZ, Toker L, Agam G, Anderson GW, Belmaker RH, Einat H. Trehalose induced antidepressant-like effects and autophagy enhancement in mice. *Psychopharmacology* 2013; **229**: 367–375.
- 48 Criollo A, Maiuri MC, Tasdemir E, Vitale I, Fiebig AA, Andrews D et al. Regulation of autophagy by the inositol trisphosphate receptor. *Cell Death Differ* 2007; **14**: 1029–1039.
- 49 Vicencio JM, Ortiz C, Criollo A, Jones AW, Kepp O, Galluzzi L et al. The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. *Cell Death Differ* 2009; **16**: 1006–1017.
- 50 Galeotti N, Vivoli E, Norcini M, Bartolini A, Ghelardini C. An antidepressant behaviour in mice carrying a gene-specific InsP3R1, InsP3R2 and InsP3R3 protein knockdown. *Neuropharmacology* 2008; **55**: 1156–1164.
- 51 O'Brien WT, Harper AD, Jove F, Woodgett JR, Maretto S, Piccolo S et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. *J Neurosci* 2004; **24**: 6791–6798.
- 52 Whitworth P, Kendall DA. Lithium selectively inhibits muscarinic receptor-stimulated inositol tetrakisphosphate accumulation in mouse cerebral cortex slices. *J Neurochem* 1988; **51**: 258–265.
- 53 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976; **72**: 248–254.
- 54 Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy* 2016; **12**: 1–222.
- 55 Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. *Mol Biol Cell* 2004; **15**: 1101–1111.
- 56 Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. *Cell Death Differ* 2011; **18**: 571–580.
- 57 Rusten TE, Stenmark H. p62, an autophagy hero or culprit? *Nat Cell Biol* 2010; **12**: 207–209.
- 58 Gould TJ, Keith RA, Bhat RV. Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. *Behav Brain Res* 2001; **118**: 95–105.
- 59 Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. *Nature* 1977; **266**: 730–732.
- 60 Einat HSA, Bersudsky Y, Belmaker RH. Prospectives for the development of animal models for the study of bipolar disorder. In: Soares JCYR (ed). *Bipolar Disorders: Basic Mechanisms and Therapeutic Implications*, 2nd edn. New York, 2000, pp 23–38.

- 61 York JD, Ponder JW, Majerus PW. Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. *Proc Natl Acad Sci USA* 1995; **92**: 5149–5153.
- 62 Spector R, Lorenzo AV. The origin of myo-inositol in brain, cerebrospinal fluid and choroid plexus. *J Neurochem* 1975; **25**: 353–354.
- 63 Bymaster FP, Carter PA, DeLapp NW, Calligaro DO, Felder CC. Receptor reserve of phosphoinositide-coupled muscarinic receptors in mouse hippocampus *in vivo*. *Brain Res* 2001; **916**: 165–171.
- 64 Devaki R, Shankar Rao S, Nadgir SM. The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain. *J Psychiatry Neurosci* 2006; **31**: 246–252.
- 65 Los GV, Artemenko IP, Hokin LE. Time-dependent effects of lithium on the agonist-stimulated accumulation of second messenger inositol 1,4,5-trisphosphate in SH-SY5Y human neuroblastoma cells. *Biochem J* 1995; **311**(Pt 1): 225–232.
- 66 Dixon JF, Lee CH, Los GV, Hokin LE. Lithium enhances accumulation of [3H]inositol radioactivity and mass of second messenger inositol 1,4,5-trisphosphate in monkey cerebral cortex slices. *J Neurochem* 1992; **59**: 2332–2335.
- 67 Levine J. Controlled trials of inositol in psychiatry. *Eur Neuropsychopharmacology* 1997; **7**: 147–155.
- 68 Chengappa KN, Levine J, Gershon S, Mallinger AG, Hardan A, Vagnucci A et al. Inositol as an add-on treatment for bipolar depression. *Bipolar Disord* 2000; **2**: 47–55.
- 69 Czech MP. PIP2 and PIP3: complex roles at the cell surface. *Cell* 2000; **100**: 603–606.
- 70 Sherman WR. *Lithium and the Cell*. Academic Press, London, United Kingdom: 1991.
- 71 Saiardi A, Bhandari R, Resnick AC, Snowman AM, Snyder SH. Phosphorylation of proteins by inositol pyrophosphates. *Science* 2004; **306**: 2101–2105.
- 72 de Bartolomeis A, Tomasetti C, Cicale M, Yuan PX, Manji HK. Chronic treatment with lithium or valproate modulates the expression of Homer1b/c and its related genes Shank and Inositol 1,4,5-trisphosphate receptor. *Eur Neuropsychopharmacol* 2012; **22**: 527–535.
- 73 Morris G, Berk M. The putative use of lithium in Alzheimer's disease. *Curr Alzheimer Res* 2016; **13**: 853–861.
- 74 Scheuing L, Chiu CT, Liao HM, Linares GR, Chuang DM. Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned? *Int J Biol Sci* 2014; **10**: 1024–1038.
- 75 Motoi Y, Shimada K, Ishiguro K, Hattori N. Lithium and autophagy. *ACS Chem Neurosci* 2014; **5**: 434–442.
- 76 Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML et al. Lithium delays progression of amyotrophic lateral sclerosis. *Proc Natl Acad Sci USA* 2008; **105**: 2052–2057.
- 77 Fabrizi C, De Vito S, Somma F, Pompili E, Catizone A, Leone S et al. Lithium improves survival of PC12 pheochromocytoma cells in high-density cultures and after exposure to toxic compounds. *Int J Cell Biol* 2014; **2014**: 135908.
- 78 Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. *Hum Mol Genet* 2008; **17**: 170–178.
- 79 Toker LB RH, Agam G A proteomics study of the effect of lithium treatment and of IMPA1 knockout reveals a similar effect on mitochondrial function and autophagy. 2016 (submitted).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016

Supplementary Information accompanies the paper on the Translational Psychiatry website (<http://www.nature.com/tp>)